Resolute

Title: RESOLUTE

Study Sponsor: Medtronic 

Principal Investigator: Michael Mooney, MD 

Study Synopsis: To evaluate the safety and effectiveness of the drug-eluting Medtronic ENDEAVOR® Resolute Zotarolimus-Eluting Coronary Stent for the treatment of coronary artery blockages. This investigational stent uses a new polymer (coating on the stent that holds the drug in place) which provides a slow release of the drug from the stent over time. 

All patients enrolled will receive the investigational stent and will undergo clinical follow-up at 30 days, 6 months, 8 months (as applicable), 9 months, 12 months, 18 months, and annually for up to 5 years. A total of 1399 patients will be enrolled in the trial at a 125 active investigational sites within the United States (US). 

Study Status: Closed to enrollment 

How do I qualify? Patients may qualify if coronary disease meets the study criteria. 

Who do I contact for more information? Gretchen Peichel RN. or contact research at 612.863.3980